Analyst Mohit Bansal of Wells Fargo maintained a Hold rating on Amgen (AMGN – Research Report), retaining the price target of $335.00.

"Inebilizumab is a humanized monoclonal antibody that causes targeted and sustained depletion of CD19-positive B cells, ...

Amgen said it achieved positive results from a Phase 3 trial of its treatment for adults with generalized myasthenia gravis, a rare autoimmune disorder.

Tuesday announced positive topline data from the Phase 3 MINT study evaluating Uplizna for the treatment of adults ...

Amgen (NASDAQ:AMGN) today announced the presentation of positive top-line results from the Phase 3 MINT trial evaluating the ...

US biotech major Amgen (Nasdaq: AMGN) has further strengthened the growing evidence for the use of Uplizna (inebilizumab-cdon ...

Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the US Food and Drug Administration (FDA) as an add-on maintenance treatment for chronic obstructive pulmonary disease (COPD). The ...

And they said Uplizna, which is in development for a muscle weakening disease called myasthenia gravis, didn’t appear as effective as already approved therapies for the condition.

A severe solar storm is headed to Earth that could stress power grids even more as the US deals with disruptions from Hurricane Milton that hit Florida .

In the MINT study, management evaluated the rare disease drug Uplizna (inebilizumab) for label expansion in generalized myasthenia gravis (gMG) indication. The HORIZON study showed that treatment ...

Shares of Amgen AMGN fell by more than 5% on Wednesday after it reported top-line data on two different drugs in the ...